June 17, 2005 |
Pfizer Inc. on Thursday said that it planned to buy Vicuron Pharmaceuticals Inc., a biotechnology company with two promising infection treatments that could soon receive regulatory approval, for $1.9 billion in cash. Pfizer hopes the acquisition will help it offset lost sales from its anti-fungal treatment Diflucan, which recently lost patent protection, and an expected slide in sales of its antibiotic Zithromax, which could face generic competition later this year.
August 15, 2000 |
Traditionally a quiet month for initial public offerings, August is shaping up as the busiest month this year and the busiest August since 1983. But investors hoping to make a killing in August's new issues have been mostly disappointed: IPOs aren't popping on their first days as they were earlier this year, even though some companies selling shares this month are doing so at marked-down prices to entice buyers. That could be good news, though, for investors with a longer time horizon.
November 5, 2003 |
A small clinical trial has shown for the first time that it is possible to use drugs to remove plaque from clogged arteries, a finding that could lead to radically new ways of treating heart disease, the No. 1 killer in the United States. Infusions of a genetically engineered mutant form of high-density lipoprotein, the so-called good cholesterol, over a five-week period were shown to reduce plaque volume in patients suffering from chest pain.